Press Releases

June 16, 2021
Ocugen Inc. Set to Join Russell 3000® Index
MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it is set to join the
Additional Formats
June 10, 2021
Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial
MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Michael Shine will be
Additional Formats
June 3, 2021
Ocugen Expands COVAXIN™ Commercialization Rights to Include Canada
Ocugen to have exclusive co-development, manufacturing, and commercialization rights to COVAXIN™ in Canada, in addition to its existing US rights MALVERN, Pa. and HYDERABAD, India, June 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering,
Additional Formats
Displaying 11 - 20 of 41